You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrenylamine
Accession NumberDB04825
TypeSmall Molecule
GroupsWithdrawn
DescriptionPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Structure
Thumb
Synonyms
1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane
DL-prenylamine
N-(1-Methyl-2-phenylethyl)-3,3-diphenyl-1-propanamine
N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine
N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin
N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
N-(3'-Phenyl-2-propyl)-1,1-diphenyl-3-propyloamine
Prenilamina
Prenylaminum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BismethinNot Available
CarditinNot Available
CorontinNot Available
CorpaxNot Available
ElecorNot Available
FalliocorNot Available
HostaginanNot Available
SegontinNot Available
SynadrinNot Available
ValecorNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK2OH82Z000
CAS number390-64-7
WeightAverage: 329.4779
Monoisotopic: 329.214349869
Chemical FormulaC24H27N
InChI KeyIFFPICMESYHZPQ-UHFFFAOYSA-N
InChI
InChI=1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3
IUPAC Name
(3,3-diphenylpropyl)(1-phenylpropan-2-yl)amine
SMILES
CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
CalmodulinProteinunknownNot AvailableHumanP62158 details
Myosin light chain kinase 2, skeletal/cardiac muscleProteinunknownNot AvailableHumanQ9H1R3 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Prenylamine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Prenylamine.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Prenylamine.Approved, Investigational
AmobarbitalThe metabolism of Prenylamine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Prenylamine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Prenylamine.Approved, Investigational
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Prenylamine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Prenylamine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Prenylamine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Prenylamine is combined with Atosiban.Approved
Atracurium besylatePrenylamine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Prenylamine.Experimental
BarbexacloneThe metabolism of Prenylamine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Prenylamine can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Prenylamine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Prenylamine.Approved
BucindololBucindolol may increase the hypotensive activities of Prenylamine.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Prenylamine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Prenylamine.Approved
CalciumThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Prenylamine.Withdrawn
CarbomycinThe metabolism of Prenylamine can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Prenylamine.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Prenylamine.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Prenylamine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Prenylamine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Prenylamine.Approved, Investigational
CimetidineThe serum concentration of Prenylamine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Prenylamine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Prenylamine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Prenylamine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Prenylamine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Prenylamine.Investigational
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Prenylamine.Experimental
DoxazosinDoxazosin may increase the hypotensive activities of Prenylamine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Prenylamine.Approved
EfavirenzThe serum concentration of Prenylamine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Prenylamine.Approved
ErythromycinThe metabolism of Prenylamine can be decreased when combined with Erythromycin.Approved, Vet Approved
FluconazoleThe serum concentration of Prenylamine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Prenylamine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Prenylamine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Prenylamine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Prenylamine.Approved, Vet Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Prenylamine.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Prenylamine.Approved
HexobarbitalThe metabolism of Prenylamine can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Prenylamine.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Prenylamine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Prenylamine.Approved, Investigational
JosamycinThe metabolism of Prenylamine can be decreased when combined with Josamycin.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Prenylamine.Approved, Investigational
KitasamycinThe metabolism of Prenylamine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Prenylamine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium Sulfate.Approved, Vet Approved
MethohexitalThe metabolism of Prenylamine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Prenylamine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Prenylamine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Prenylamine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Prenylamine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Prenylamine.Approved
MivacuriumPrenylamine may increase the neuromuscular blocking activities of Mivacurium.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Prenylamine.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Prenylamine.Experimental
NafcillinThe metabolism of Prenylamine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Prenylamine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Prenylamine.Approved
NitroprussidePrenylamine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Prenylamine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Prenylamine.Approved, Vet Approved
OleandomycinThe metabolism of Prenylamine can be decreased when combined with Oleandomycin.Vet Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Prenylamine.Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Prenylamine.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Prenylamine.Approved
PentobarbitalThe metabolism of Prenylamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Prenylamine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Prenylamine.Approved, Vet Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Prenylamine.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Prenylamine.Approved
PrimidoneThe metabolism of Prenylamine can be increased when combined with Primidone.Approved, Vet Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Prenylamine.Experimental
RapacuroniumPrenylamine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RifabutinThe serum concentration of Prenylamine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Prenylamine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Prenylamine can be decreased when it is combined with Rifapentine.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Prenylamine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prenylamine.Approved, Vet Approved
SecobarbitalThe metabolism of Prenylamine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Prenylamine.Approved
SilodosinSilodosin may increase the hypotensive activities of Prenylamine.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Prenylamine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Prenylamine.Approved, Investigational
SolithromycinThe metabolism of Prenylamine can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Prenylamine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Prenylamine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Prenylamine.Approved
TelithromycinThe metabolism of Prenylamine can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Prenylamine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Prenylamine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Prenylamine.Approved
ThiamylalThe metabolism of Prenylamine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Prenylamine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Prenylamine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Prenylamine.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Prenylamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Prenylamine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Prenylamine.Approved, Investigational
TroleandomycinThe metabolism of Prenylamine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Prenylamine can be decreased when combined with Tylosin.Vet Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Prenylamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US3152173
General ReferencesNot Available
External Links
ATC CodesC01DX52C01DX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9774
Caco-2 permeable+0.8194
P-glycoprotein substrateSubstrate0.5313
P-glycoprotein inhibitor IInhibitor0.59
P-glycoprotein inhibitor IINon-inhibitor0.7214
Renal organic cation transporterInhibitor0.6263
CYP450 2C9 substrateNon-substrate0.7387
CYP450 2D6 substrateSubstrate0.8796
CYP450 3A4 substrateNon-substrate0.6941
CYP450 1A2 substrateInhibitor0.8455
CYP450 2C9 inhibitorNon-inhibitor0.9304
CYP450 2D6 inhibitorInhibitor0.927
CYP450 2C19 inhibitorInhibitor0.6787
CYP450 3A4 inhibitorNon-inhibitor0.6841
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6512
Ames testNon AMES toxic0.8094
CarcinogenicityNon-carcinogens0.8812
BiodegradationNot ready biodegradable0.86
Rat acute toxicity3.0889 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7311
hERG inhibition (predictor II)Inhibitor0.7538
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point36.5 °CPhysProp
water solubility50 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility3.54e-05 mg/mLALOGPS
logP5.89ALOGPS
logP6.12ChemAxon
logS-7ALOGPS
pKa (Strongest Basic)10.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.09 m3·mol-1ChemAxon
Polarizability39.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Myosin light chain kinase activity
Specific Function:
Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain.
Gene Name:
MYLK2
Uniprot ID:
Q9H1R3
Molecular Weight:
64684.295 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:28 / Updated on August 17, 2016 12:24